Lenalidomid Axiromed

Lenalidomide, the active ingredient in Lenalidomid Axiromed, is an immunomodulatory drug presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, particularly multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomid Axiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery across multiple regions.

Lenalidomide is used as an antineoplastic agent targeting malignant plasma cells and dysplastic bone‑marrow clones.

Multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Anemia - Constipation - Rash

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Severe neutropenia with infection risk - Secondary primary malignancies - Hypersensitivity reactions (including Stevens‑Johnson syndrome) - Cardiac arrhythmias - Hepatotoxicity

When prescribing lenalidomide, several safety considerations are required.

Pregnancy: contraindicated (Category X); avoid use in pregnant women. Thrombosis risk: assess patient history and consider prophylactic anticoagulation. Renal impairment: adjust dose based on renal function. Hematologic monitoring: perform regular CBC to detect cytopenias. Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. Store at room temperature: keep below 25 °C, protect from moisture and light in original container.

Lenalidomide can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Live vaccines: risk of infection due to immunosuppression. - Thalidomide: additive teratogenic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): increased bleeding risk. - CYP3A4 inducers (rifampin, phenytoin): may reduce efficacy. - Non‑live vaccines: monitor immune response.